Αρχική World News ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in... World News ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC Από Ogkologos - 21 Μαΐου, 2026 309 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TOMBOLA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... 23 Μαΐου, 2024 Surprise! Financial Assistance To Help With Your Medical Bills May Be... 20 Δεκεμβρίου, 2023 ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany 8 Μαΐου, 2024 COVID-19 Vaccine Myth Busters 28 Ιανουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... Listening to Patient Narratives How the history of medicine influenced our perception of cancer Cancer research could revive the UK’s ailing public finances